2025 Q4 -tulosraportti
Vain PDF
133 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·29 min sittenCircio cracks the price code for CAR-T. Today's CAR-T treatment costs 4–10 million kroner per patient and requires weeks of expensive cell cultivation in cleanrooms. Circio moves the process directly into the body (in vivo): With the help of circVEC, the patient's own cells are reprogrammed via a standard injection. The result is radical cost reduction, scalable off-the-shelf production, and a real democratization of cancer treatment.
BMS today terminated an agreement with a company that produced their CAR-T product - the traditional cell cultivation. If I understood comments correctly, investments in such production facilities are already being dramatically reduced. The trend is already shifting towards production technologies for in vivo CAR-T, which is expected to take over. No more is being invested in technologies that they believe will be phased out.
·1 t sittenThe journey has already begun. 🚀 As you read this, people are in a lab at Karolinska working on circVec. Partners on three continents are testing it in their systems. One of the world's five largest pharmaceutical companies is running it in vivo — with its own money. 🔬 Ape validation is on the plan. Four readouts in the window. ESGCT in Hamburg in October. None of this is waiting for you. It's already rolling. ⏳ You can only choose whether you are on the inside or the outside when the result comes. We know what we own. ♟️🧱🍷
·1 t sittenNow it is the fear of missing out "FOMO" that drives the prices. So far, there is also no news other than new board members, invitations to hold lectures, and new collaboration projects. If one looks at the turnover, many new shareholders must have joined. One also sees that the possibilities to push the price up and down on the same day are blocked by new investors who are in because they believe in the case. Turnover exploded after the mention in Investornytt. A very well-structured article that, with relatively accessible language, explained what Circio's product(s) actually are about. Yes, the price can go south if apa fails in the clinical phase, but if this is a complete success, lift your gaze 10 cm up and look at the development over 1 year. 2147.65%. This is only based on buyers with some good intuition, greed, and hope. From the company's side, indications and tactical marketing.... The same can happen again if everything works out.If you believe Espen Teigland at Investornytt is such a "MoneyMaker" that he is responsible for 200 million in turnover in one day, then I think you overestimate him. Look at the shareholder list today. Finally, larger investors are coming in, funds and foreign banks. It's bigger money that has started to move.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
133 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29 min sittenCircio cracks the price code for CAR-T. Today's CAR-T treatment costs 4–10 million kroner per patient and requires weeks of expensive cell cultivation in cleanrooms. Circio moves the process directly into the body (in vivo): With the help of circVEC, the patient's own cells are reprogrammed via a standard injection. The result is radical cost reduction, scalable off-the-shelf production, and a real democratization of cancer treatment.BMS today terminated an agreement with a company that produced their CAR-T product - the traditional cell cultivation. If I understood comments correctly, investments in such production facilities are already being dramatically reduced. The trend is already shifting towards production technologies for in vivo CAR-T, which is expected to take over. No more is being invested in technologies that they believe will be phased out.
- ·1 t sittenThe journey has already begun. 🚀 As you read this, people are in a lab at Karolinska working on circVec. Partners on three continents are testing it in their systems. One of the world's five largest pharmaceutical companies is running it in vivo — with its own money. 🔬 Ape validation is on the plan. Four readouts in the window. ESGCT in Hamburg in October. None of this is waiting for you. It's already rolling. ⏳ You can only choose whether you are on the inside or the outside when the result comes. We know what we own. ♟️🧱🍷
- ·1 t sittenNow it is the fear of missing out "FOMO" that drives the prices. So far, there is also no news other than new board members, invitations to hold lectures, and new collaboration projects. If one looks at the turnover, many new shareholders must have joined. One also sees that the possibilities to push the price up and down on the same day are blocked by new investors who are in because they believe in the case. Turnover exploded after the mention in Investornytt. A very well-structured article that, with relatively accessible language, explained what Circio's product(s) actually are about. Yes, the price can go south if apa fails in the clinical phase, but if this is a complete success, lift your gaze 10 cm up and look at the development over 1 year. 2147.65%. This is only based on buyers with some good intuition, greed, and hope. From the company's side, indications and tactical marketing.... The same can happen again if everything works out.If you believe Espen Teigland at Investornytt is such a "MoneyMaker" that he is responsible for 200 million in turnover in one day, then I think you overestimate him. Look at the shareholder list today. Finally, larger investors are coming in, funds and foreign banks. It's bigger money that has started to move.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
133 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·29 min sittenCircio cracks the price code for CAR-T. Today's CAR-T treatment costs 4–10 million kroner per patient and requires weeks of expensive cell cultivation in cleanrooms. Circio moves the process directly into the body (in vivo): With the help of circVEC, the patient's own cells are reprogrammed via a standard injection. The result is radical cost reduction, scalable off-the-shelf production, and a real democratization of cancer treatment.BMS today terminated an agreement with a company that produced their CAR-T product - the traditional cell cultivation. If I understood comments correctly, investments in such production facilities are already being dramatically reduced. The trend is already shifting towards production technologies for in vivo CAR-T, which is expected to take over. No more is being invested in technologies that they believe will be phased out.
- ·1 t sittenThe journey has already begun. 🚀 As you read this, people are in a lab at Karolinska working on circVec. Partners on three continents are testing it in their systems. One of the world's five largest pharmaceutical companies is running it in vivo — with its own money. 🔬 Ape validation is on the plan. Four readouts in the window. ESGCT in Hamburg in October. None of this is waiting for you. It's already rolling. ⏳ You can only choose whether you are on the inside or the outside when the result comes. We know what we own. ♟️🧱🍷
- ·1 t sittenNow it is the fear of missing out "FOMO" that drives the prices. So far, there is also no news other than new board members, invitations to hold lectures, and new collaboration projects. If one looks at the turnover, many new shareholders must have joined. One also sees that the possibilities to push the price up and down on the same day are blocked by new investors who are in because they believe in the case. Turnover exploded after the mention in Investornytt. A very well-structured article that, with relatively accessible language, explained what Circio's product(s) actually are about. Yes, the price can go south if apa fails in the clinical phase, but if this is a complete success, lift your gaze 10 cm up and look at the development over 1 year. 2147.65%. This is only based on buyers with some good intuition, greed, and hope. From the company's side, indications and tactical marketing.... The same can happen again if everything works out.If you believe Espen Teigland at Investornytt is such a "MoneyMaker" that he is responsible for 200 million in turnover in one day, then I think you overestimate him. Look at the shareholder list today. Finally, larger investors are coming in, funds and foreign banks. It's bigger money that has started to move.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt